UCB - Cost Of Sales


UCB reported EUR1.07B in Cost of Sales for its fiscal semester ending in December of 2025.





Cost Of Sales Change Date
Alcon AG USD 1.18B 26M Mar/2026
Almirall EUR 199.26M 7.76M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
argenx SE USD 145M 24M Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Bayer EUR 5.23B 731M Mar/2026
Genmab DKK 84M 19M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
GRIFOLS EUR 1.17B 90M Jun/2026
Hikma Pharmaceutical USD 959M 492.5M Dec/2025
Lakefront Biotherapeutics EUR 4.8M 4.34M Mar/2026
Lonza CHF 2.28B 189M Jun/2025
Merck EUR 2.07B 219M Mar/2026
Novartis USD 3.71B 251M Jun/2026
Orion EUR 181.7M 18M Jun/2026
Recordati EUR 199.38M 3.22M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
UCB EUR 1.07B 146M Dec/2025
Unibail Rodamco EUR 546.4M 9.4M Dec/2025